# Citigroup Inc: financial statements, quarterly

C · NYSE · CIK 831001 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/c.md) · [Financials](/companies/c/financials.md) · [Filings](/companies/c/filings.md) · [Insiders](/companies/c/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/c/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [21.4](/filings/0000831001-24-000051.md) | [19.4](/filings/0000831001-24-000100.md) | [20.1](/filings/0000831001-24-000134.md) | [17.0 d](/filings/0000831001-26-000011.md) | [21.0](/filings/0000831001-25-000086.md) | [20.0](/filings/0000831001-25-000131.md) | [20.2](/filings/0000831001-25-000154.md) | [19.5 d](/filings/0000831001-26-000011.md) | [21.6](/filings/0000831001-25-000086.md) | [21.7](/filings/0000831001-25-000131.md) | [22.1](/filings/0000831001-25-000154.md) | [19.9 d](/filings/0000831001-26-000011.md) |
| Cost of revenue | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $bn | [16.0](/filings/0000831001-24-000051.md) | [18.7](/filings/0000831001-24-000100.md) | [21.0](/filings/0000831001-23-000132.md) | [22.6 d](/filings/0000831001-24-000033.md) | [22.7](/filings/0000831001-24-000051.md) | [22.5](/filings/0000831001-24-000100.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $bn | [1.5](/filings/0000831001-24-000051.md) | [1.1](/filings/0000831001-24-000100.md) | [1.2](/filings/0000831001-24-000134.md) | [(0.3) d](/filings/0000831001-26-000011.md) | [1.1](/filings/0000831001-25-000086.md) | [1.0](/filings/0000831001-25-000131.md) | [1.1](/filings/0000831001-25-000154.md) | [0.9 d](/filings/0000831001-26-000011.md) | [1.3](/filings/0000831001-25-000086.md) | [1.2](/filings/0000831001-25-000131.md) | [1.6](/filings/0000831001-25-000154.md) | [1.3 d](/filings/0000831001-26-000011.md) |
| Net income | $bn | [4.6](/filings/0000831001-24-000051.md) | [2.9](/filings/0000831001-24-000100.md) | [3.5](/filings/0000831001-24-000134.md) | [(1.8) d](/filings/0000831001-26-000011.md) | [3.4](/filings/0000831001-25-000086.md) | [3.2](/filings/0000831001-25-000131.md) | [3.2](/filings/0000831001-25-000154.md) | [2.9 d](/filings/0000831001-26-000011.md) | [4.1](/filings/0000831001-25-000086.md) | [4.0](/filings/0000831001-25-000131.md) | [3.8](/filings/0000831001-25-000154.md) | [2.5 d](/filings/0000831001-26-000011.md) |
| Diluted EPS | $ per share | [2.19](/filings/0000831001-24-000051.md) | [1.33](/filings/0000831001-24-000100.md) | [1.63](/filings/0000831001-24-000134.md) | not reported | [1.58](/filings/0000831001-25-000086.md) | [1.52](/filings/0000831001-25-000131.md) | [1.51](/filings/0000831001-25-000154.md) | not reported | [1.96](/filings/0000831001-25-000086.md) | [1.96](/filings/0000831001-25-000131.md) | [1.86](/filings/0000831001-25-000154.md) | not reported |
| Basic EPS | $ per share | [2.21](/filings/0000831001-24-000051.md) | [1.34](/filings/0000831001-24-000100.md) | [1.64](/filings/0000831001-24-000134.md) | not reported | [1.59](/filings/0000831001-25-000086.md) | [1.54](/filings/0000831001-25-000131.md) | [1.53](/filings/0000831001-25-000154.md) | not reported | [2.00](/filings/0000831001-25-000086.md) | [1.98](/filings/0000831001-25-000131.md) | [1.89](/filings/0000831001-25-000154.md) | not reported |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $bn | [2,455](/filings/0000831001-23-000055.md) | [2,424](/filings/0000831001-23-000097.md) | [2,368](/filings/0000831001-23-000132.md) | [2,412](/filings/0000831001-26-000011.md) | [2,433](/filings/0000831001-24-000051.md) | [2,406](/filings/0000831001-24-000100.md) | [2,431](/filings/0000831001-24-000134.md) | [2,353](/filings/0000831001-26-000011.md) | [2,572](/filings/0000831001-25-000086.md) | [2,623](/filings/0000831001-25-000131.md) | [2,642](/filings/0000831001-25-000154.md) | [2,657](/filings/0000831001-26-000011.md) |
| Total liabilities | $bn | [2,246](/filings/0000831001-23-000055.md) | [2,214](/filings/0000831001-23-000097.md) | [2,158](/filings/0000831001-23-000132.md) | [2,206](/filings/0000831001-25-000067.md) | [2,225](/filings/0000831001-24-000051.md) | [2,197](/filings/0000831001-24-000100.md) | [2,221](/filings/0000831001-24-000134.md) | [2,144](/filings/0000831001-26-000011.md) | [2,358](/filings/0000831001-25-000086.md) | [2,409](/filings/0000831001-25-000131.md) | [2,429](/filings/0000831001-25-000154.md) | [2,443](/filings/0000831001-26-000011.md) |
| Long-term debt | $bn | [280](/filings/0000831001-23-000055.md) | [275](/filings/0000831001-23-000097.md) | [276](/filings/0000831001-23-000132.md) | [287](/filings/0000831001-25-000067.md) | [285](/filings/0000831001-24-000051.md) | [280](/filings/0000831001-24-000100.md) | [299](/filings/0000831001-24-000134.md) | [287](/filings/0000831001-26-000011.md) | [296](/filings/0000831001-25-000086.md) | [318](/filings/0000831001-25-000131.md) | [316](/filings/0000831001-25-000154.md) | [316](/filings/0000831001-26-000011.md) |
| Short-term borrowings | $bn | [40.2](/filings/0000831001-23-000055.md) | [40.4](/filings/0000831001-23-000097.md) | [43.2](/filings/0000831001-23-000132.md) | [37.5](/filings/0000831001-25-000067.md) | [31.9](/filings/0000831001-24-000051.md) | [38.7](/filings/0000831001-24-000100.md) | [41.3](/filings/0000831001-24-000134.md) | [48.5](/filings/0000831001-26-000011.md) | [49.1](/filings/0000831001-25-000086.md) | [55.6](/filings/0000831001-25-000131.md) | [54.8](/filings/0000831001-25-000154.md) | [51.9](/filings/0000831001-26-000011.md) |
| Shareholders' equity | $bn | [208](/filings/0000831001-23-000055.md) | [209](/filings/0000831001-23-000097.md) | [210](/filings/0000831001-23-000132.md) | [205](/filings/0000831001-25-000067.md) | [207](/filings/0000831001-24-000051.md) | [208](/filings/0000831001-24-000100.md) | [209](/filings/0000831001-24-000134.md) | [209](/filings/0000831001-26-000011.md) | [212](/filings/0000831001-25-000086.md) | [213](/filings/0000831001-25-000131.md) | [213](/filings/0000831001-25-000154.md) | [212](/filings/0000831001-26-000011.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $bn | [(30.5)](/filings/0000831001-24-000051.md) | [(54.1) d](/filings/0000831001-24-000100.md) | [15.8 d](/filings/0000831001-24-000134.md) | [(4.7) d](/filings/0000831001-26-000011.md) | [(10.8)](/filings/0000831001-25-000086.md) | [(17.0) d](/filings/0000831001-25-000131.md) | [(16.7) d](/filings/0000831001-25-000154.md) | [24.8 d](/filings/0000831001-26-000011.md) | [(58.7)](/filings/0000831001-25-000086.md) | [(36.6) d](/filings/0000831001-25-000131.md) | [1.1 d](/filings/0000831001-25-000154.md) | [26.6 d](/filings/0000831001-26-000011.md) |
| Capital expenditure | $bn | [1.6](/filings/0000831001-24-000051.md) | [1.5 d](/filings/0000831001-24-000100.md) | [1.7 d](/filings/0000831001-24-000134.md) | [1.8 d](/filings/0000831001-26-000011.md) | [1.6](/filings/0000831001-25-000086.md) | [1.6 d](/filings/0000831001-25-000131.md) | [1.6 d](/filings/0000831001-25-000154.md) | [1.7 d](/filings/0000831001-26-000011.md) | [1.5](/filings/0000831001-25-000086.md) | [1.8 d](/filings/0000831001-25-000131.md) | [1.6 d](/filings/0000831001-25-000154.md) | [1.6 d](/filings/0000831001-26-000011.md) |
| Dividends paid | $bn | [1.3](/filings/0000831001-24-000051.md) | [1.3 d](/filings/0000831001-24-000100.md) | [1.4 d](/filings/0000831001-24-000134.md) | [1.3 d](/filings/0000831001-26-000011.md) | [1.3](/filings/0000831001-25-000086.md) | [1.3 d](/filings/0000831001-25-000131.md) | [1.3 d](/filings/0000831001-25-000154.md) | [1.3 d](/filings/0000831001-26-000011.md) | [1.3](/filings/0000831001-25-000086.md) | [1.3 d](/filings/0000831001-25-000131.md) | [1.4 d](/filings/0000831001-25-000154.md) | [1.4 d](/filings/0000831001-26-000011.md) |
| Share repurchases | $bn | [0.0](/filings/0000831001-24-000051.md) | [1.0 d](/filings/0000831001-24-000100.md) | [0.4 d](/filings/0000831001-24-000134.md) | [0.5 d](/filings/0000831001-26-000011.md) | [0.4](/filings/0000831001-25-000086.md) | [0.1 d](/filings/0000831001-25-000131.md) | [1.0 d](/filings/0000831001-25-000154.md) | [1.0 d](/filings/0000831001-26-000011.md) | [1.8](/filings/0000831001-25-000086.md) | [2.0 d](/filings/0000831001-25-000131.md) | [5.0 d](/filings/0000831001-25-000154.md) | [4.5 d](/filings/0000831001-26-000011.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1,988](/filings/0000831001-23-000055.md) | [1,958](/filings/0000831001-23-000097.md) | [1,955](/filings/0000831001-23-000132.md) | [1,964](/filings/0000831001-24-000051.md) | [1,969](/filings/0000831001-24-000100.md) | [1,952](/filings/0000831001-24-000134.md) | [1,943](/filings/0000831001-25-000086.md) | [1,946](/filings/0000831001-25-000131.md) | [1,940](/filings/0000831001-25-000154.md) | [1,920](/filings/0000831001-25-000086.md) | [1,893](/filings/0000831001-25-000131.md) | [1,863](/filings/0000831001-25-000154.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,749,319,009 at 2026-01-31, from the cover of the [10-K filed 2026-02-20](/filings/0000831001-26-000011.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.